A Study of LY4178256 in Healthy Participants
Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07698210
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to check how much LY4178256 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 7 months and will include either 7 or 12 visits depending on the assigned treatment.
Interventions
-
LY4178256
(Drug)
Administered intravenously (IV)
-
Placebo
(Drug)
Administered IV
Eligibility criteria
Conditions
Locations
- Collaborative Neuroscience Network - CNS — Los Alamitos, California, United States
- ICON — Salt Lake City, Utah, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record